Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases.

doi:10.1016/j.ejmech.2014.04.075

Paper

Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases.

Published Jun 23, 2014 · Gema C González-Muñoz, Mariana P. Arce, C. Pérez

European journal of medicinal chemistry

Q2 SJR score

13

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

Dibenzo[1,4,5]thiadiazepines show neuroprotective properties and potential in treating neurodegenerative diseases, with no cytotoxic effects and CNS-permeable properties.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases.

Sign up to use Study Snapshot

References

Antioxidant therapy: still in search of the 'magic bullet'.

Antioxidant therapy shows potential in preclinical studies but has little benefit in human trials, suggesting the need for further optimization and development of effective delivery systems.

Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia

ITH33/IQM9.21 effectively protects vulnerable neurons in ischemic penumbra by reducing calcium overload, providing mitochondrial protection, and antioxidant actions.

Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Neurodegenerative drug discovery should focus on targeting multiple key players and designing small molecules with multiple modes of action to develop more effective treatments.

2013 Alzheimer's disease facts and figures

Alzheimer's disease is the sixth leading cause of death in the United States, with long-distance caregivers facing unique challenges and high out-of-pocket costs.

Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.

SC001, a GSK-3 inhibitor, shows potential as a neuroprotective agent for Parkinson's disease, offering a new pharmacological option for disease-modifying treatment.

Citations

Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases

Heterocyclic compounds show exceptional therapeutic potential in developing new effective treatments for Alzheimer's and Parkinson's diseases.

Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease

Natural compounds derived from plants show potential benefits for Alzheimer's disease treatment by targeting various enzymes and contributing to the development of new therapies.

Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer’s Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside

Antioxidants targeting mitochondrial-derived reactive oxygen species show potential in halting Alzheimer's disease progression, but clinical studies show inconsistent results due to various factors.

Sequential N ‐Arylation and Intramolecular Imine Addition Reaction of Indoloazomethine Ylides with Arynes for the Synthesis of Thiadiazepine Derivatives

This study demonstrates a metal-free method for synthesizing 1,4-thiadiazepines and indoloindolizines using indoloazomethine ylides and 2-(trimethylsilyl)aryl triflates.

Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.

Donepezil-flavonoid hybrids show neurogenic and neuroprotective properties, inhibiting key Alzheimer's disease enzymes and promoting neural stem cell maturation.